Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma-Reference-Cited by-同舟云学术

Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma

Published:2019-09-01 Issue:9 Volume:5 Page:1293
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Landgren Ola¹,Hofmann Jonathan N.²,McShane Charlene M.³,Santo Loredana²,Hultcrantz Malin¹⁴,Korde Neha¹,Mailankody Sham¹,Kazandjian Dickran⁵,Murata Kazunori⁶,Thoren Katie⁶,Ramanathan Lakshmi⁶,Dogan Ahmet⁷,Rustad Even¹,Lu Sydney X.¹,Akhlaghi Theresia¹,Kristinsson Sigurdur Y.⁴⁸,Björkholm Magnus⁴,Devlin Sean⁹,Purdue Mark P.²,Pfeiffer Ruth M.²,Turesson Ingemar¹⁰

Affiliation:

1. Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

2. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland

3. Cancer Epidemiology and Health Services Research Group, Centre for Public Health, Queen’s University, Belfast, Northern Ireland, United Kingdom

4. Division of Hematology, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden

5. Multiple Myeloma Section, National Cancer Institute, Bethesda, Maryland

6. Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

7. Department of Hematopathology, Memorial Sloan Kettering Cancer Center, New York, New York

8. Faculty of Medicine, University of Iceland, Reykjavik, Iceland

9. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York

10. Myeloma Section, Department of Medicine, University Hospital of Malmo, Malmo, Sweden

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2738419/jamaoncology_landgren_2019_oi_190042.pdf

Reference23 articles.

1. Cancer statistics, 2017.;Siegel;CA Cancer J Clin,2017

2. Multiple myeloma.;Kyle;Blood,2008

3. Myeloma kidney: improving clinical outcomes?;Haynes;Adv Chronic Kidney Dis,2012

4. From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention.;Landgren;Clin Cancer Res,2011

5. Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey.;Landgren;Blood Cancer J,2017

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Fracture Phenotypes in Women and Men of 50 Years and Older with a Recent Clinical Fracture;Current Osteoporosis Reports;2024-09-10

2. Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance;Blood Cancer Journal;2024-08-27

3. Genotypic identification of polyclonal plasma cells in plasma cell dyscrasias shows an aberrant single-cell phenotype with clinical implications;2024-05-27

4. Severe and continuous immunoparesis during induction or maintenance therapy in nontransplant patients with multiple myeloma is a sign of poor prognosis;Hematology;2024-03-12

5. An overview of multiple myeloma: A monoclonal plasma cell malignancy’s diagnosis, management, and treatment modalities;Saudi Journal of Biological Sciences;2024-02